Abstract
Tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) inhibitors are among the most potent treatments for inflammatory arthropathies including rheumatoid arthritis, psoriasis, and spondyloarthropathies. The availability of these biologic agents have revolutionized the management of these conditions and improved patient outcomes. Though generally safe, these biologics may contribute to the induction or exacerbation of colitis. This paradoxical colitis has been observed in patients on TNF-α inhibitor etanercept and IL-17 inhibitors (secukinumab and ixekizumab). We report a case of a 46-year-old female with psoriasis and psoriatic arthritis who presented with gastrointestinal symptoms after treatment with etanercept and IL-17 inhibitors. She was later diagnosed with paradoxical indeterminate colitis that was masked and treated by subsequent biologics given for her RA and psoriatic arthritis. In this report, we will discuss the importance of considering paradoxical colitis in the differential diagnosis for patients even several years after TNF-α/IL-17 inhibitor initiation and explain why careful consideration must be made when initiating these colitis-inducing agents to treat patients with inflammatory disorders.
This is a preview of subscription content, log in via an institution to check access.
References
Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, Dawwas GK, Weiss A, Constant BD, McCauley M, Haynes K, Yang JY, Schaubel DE, Hurtado-Lorenzo A, Kappelman MD. Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States. Gastroenterology 2023;165:1197-1205.e2. https://doi.org/10.1053/j.gastro.2023.07.003.
Zhang Y-Z. Inflammatory bowel disease: Pathogenesis. World Journal of Gastroenterology 2014;20:91. https://doi.org/10.3748/wjg.v20.i1.91.
Fu Y, Lee C-H, Chi C-C. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatology 2018;154:1417. https://doi.org/10.1001/jamadermatol.2018.3631.
Mihai IR, Burlui AM, Rezus II, Mihai C, Macovei LA, Cardoneanu A, Gavrilescu O, Dranga M, Rezus E. Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review. Life 2023;13:1779. https://doi.org/10.3390/life13081779.
Deng Z, Wang S, Wu C, Wang C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Frontiers in Pharmacology 2023;14:1124628. https://doi.org/10.3389/fphar.2023.1124628.
Akiyama S, Sakuraba A. Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases. Journal of Translational Autoimmunity 2021;4:100104. https://doi.org/10.1016/j.jtauto.2021.100104.
Wang, J., Bhatia, A., Cleveland, N. K., Gupta, N., Dalal, S., Rubin, D. T., & Sakuraba, A. (2018). Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Reports Journal, 5, e56. https://doi.org/10.14309/crj.2018.56
Fieldhouse, K. A., Ukaibe, S., Crowley, E. L., Khanna, R., O’Toole, A., & Gooderham, M. J. (2020). Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs in Context, 9, 2020-2–1. https://doi.org/10.7573/dic.2020-2-1
Haidari, W., Al-Naqshabandi, S., Ahn, C. S., Bloomfeld, R. S., & Feldman, S. R. (2019). Asymptomatic Crohn’s disease identified in a patient being treated with secukinumab: A case report. SAGE Open Medical Case Reports, 7, 2050313X1989358. https://doi.org/10.1177/2050313X19893580
Jang D, Lee A-H, Shin H-Y, Song H-R, Park J-H, Kang T-B, Lee S-R, Yang S-H. The role of Tumor Necrosis Factor Alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. International Journal of Molecular Sciences 2021;22:2719. https://doi.org/10.3390/ijms22052719.
Tolu, S., Rezvani, A., Hindioglu Dogan, N., & Çalkın Korkmaz, M. (2018). Etanercept-induced Crohn’s disease in ankylosing spondylitis: A case report and review of the literature. Rheumatology International, 38. https://doi.org/10.1007/s00296-018-4165-3
Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, Nørgård BM. Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2019;50:289–294. https://doi.org/10.1111/apt.15370.
Santiago P, Braga-Neto MB, Loftus EV. Novel Therapies for Patients With Inflammatory Bowel Disease. Gastroenterology & Hepatology 2022;18:453–465.
Ranasinghe, I. R., & Hsu, R. (2023). Crohn Disease. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK436021/
Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. (2012). In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. http://www.ncbi.nlm.nih.gov/books/NBK548069/
Author information
Authors and Affiliations
Contributions
S.H. and S.D. wrote the main manuscript text. S.H., S.D., and A.G.C, prepared figures. R.B., J.L, C.X.W, J.G, and A.G.C contributed to the clinical discussion and edited the manuscript. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Huynh, S., Achalu, S., Berry, R. et al. Some Drugs Have Two Faces: Paradoxical Colitis in a Patient with Psoriatic Arthritis Previously Treated with Etanercept and IL-17 Inhibitors. Dig Dis Sci (2024). https://doi.org/10.1007/s10620-024-08380-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10620-024-08380-2